MetVital, Inc.
- Biotech or pharma, therapeutic R&D
MetVital wishes to take a patented Phase 2 small molecule to drug approval for Cancer-Related Cognitive Impairment (CRCI, Chemo-Brain, Brain Fog). 49% of cancer patients report Cognitive Impairment, and there is no approved drug for this indication. Looking for a Phase 3 Partner or Out-License of this asset.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}